{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:09:22Z","timestamp":1792724962978,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.drudis.2024.104113","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T15:04:36Z","timestamp":1722006276000},"page":"104113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["New developments in celiac disease treatments"],"prefix":"10.1016","volume":"29","author":[{"given":"Franziska","family":"Buri\u00e1nek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Marinkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104113_b0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2011-301346","article-title":"The Oslo definitions for coeliac disease and related terms","volume":"62","author":"Ludvigsson","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2024.104113_b0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-019-1380-z","article-title":"Celiac disease: a comprehensive current review","volume":"17","author":"Caio","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.drudis.2024.104113_b0015","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/2050640619844125","article-title":"European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders","volume":"7","author":"Al-Toma","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.drudis.2024.104113_b0020","doi-asserted-by":"crossref","first-page":"5997624","DOI":"10.1155\/2022\/5997624","article-title":"Diagnostic delay in coeliac disease: a survey among Danish patients","volume":"2022","author":"K\u00e5rhus","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.104113_b0025","doi-asserted-by":"crossref","first-page":"I231","DOI":"10.1136\/bmj.l231","article-title":"Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort","volume":"364","author":"Kahrs","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.drudis.2024.104113_b0030","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/ajg.2012.130","article-title":"The incidence and risk of celiac disease in a healthy US adult population","volume":"107","author":"Riddle","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.drudis.2024.104113_b0035","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1542\/peds.2009-1200","article-title":"Infectious disease and risk of later celiac disease in childhood","volume":"125","author":"Welander","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.drudis.2024.104113_b0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/joim.13120","article-title":"Coeliac disease and noncoeliac wheat or gluten sensitivity","volume":"288","author":"Rej","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.drudis.2024.104113_b0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2032441","article-title":"A randomized trial of a transglutaminase 2 inhibitor for celiac disease","volume":"385","author":"Schuppan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104113_b0050","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1136\/gutjnl-2021-326257","article-title":"Immunopathogenesis and environmental triggers in coeliac disease","volume":"71","author":"Levescot","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2024.104113_b0055","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-020-2003-8","article-title":"IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease","volume":"578","author":"Abadie","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104113_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-pathmechdis-031521-032634","article-title":"The immunobiology and pathogenesis of celiac disease","volume":"18","author":"Iversen","year":"2023","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.drudis.2024.104113_b0065","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ajg.2014.29","article-title":"Patient perception of treatment burden is high in celiac disease compared with other common conditions","volume":"109","author":"Shah","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.drudis.2024.104113_b0070","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000066757","article-title":"Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage","volume":"66","author":"Ciacci","year":"2002","journal-title":"Digestion"},{"key":"10.1016\/j.drudis.2024.104113_b0075","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2036.2009.03992.x","article-title":"Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet","volume":"29","author":"Lanzini","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104113_b0080","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/apt.12621","article-title":"Predictors of persistent villous atrophy in coeliac disease: a population-based study","volume":"39","author":"Lebwohl","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104113_b0085","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ajg.2010.10","article-title":"Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet","volume":"105","author":"Rubio-Tapia","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.drudis.2024.104113_b0090","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/apt.12510","article-title":"Optimising delivery of care in coeliac disease \u2013 comparison of the benefits of repeat biopsy and serological follow-up","volume":"38","author":"Sharkey","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104113_b0095","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.14309\/ajg.0000000000001139","article-title":"Persistent villous atrophy in de novo adult patients with celiac disease and strict control of gluten-free diet adherence: a multicenter prospective study (CADER Study)","volume":"116","author":"Fern\u00e1ndez-Ba\u00f1ares","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.drudis.2024.104113_b0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-159-3-201308060-00006","article-title":"Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study","volume":"159","author":"Lebwohl","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.drudis.2024.104113_b0105","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1210\/jc.2013-3164","article-title":"Persistent mucosal damage and risk of fracture in celiac disease","volume":"99","author":"Lebwohl","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.drudis.2024.104113_b0110","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/gutjnl-2023-329751","article-title":"Persistent villous atrophy predicts development of complications and mortality in adult patients with coeliac disease: a multicentre longitudinal cohort study and development of a score to identify high-risk patients","volume":"72","author":"Schiepatti","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2024.104113_b0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jval.2019.07.018","article-title":"Concepts and instruments for patient-reported outcome assessment in celiac disease: literature review and experts\u2019 perspectives","volume":"23","author":"Clifford","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.drudis.2024.104113_b0120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fped.2019.00193","article-title":"Evolving therapy for celiac disease","volume":"7","author":"Yoosuf","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.drudis.2024.104113_b0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41575-020-00378-1","article-title":"Current and emerging therapies for coeliac disease","volume":"18","author":"Kivel\u00e4","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.104113_b0130","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s40265-022-01784-2","article-title":"Novel drug therapeutics in celiac disease: a pipeline review","volume":"82","author":"Varma","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2024.104113_b0135","doi-asserted-by":"crossref","first-page":"15108","DOI":"10.3390\/ijms232315108","article-title":"Replacing the burden of the gluten free diet: then, now, and the future","volume":"23","author":"Nemteanu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104113_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102268","article-title":"Celiac disease: new therapies on the horizon","volume":"66","author":"Dieckman","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.drudis.2024.104113_b0145","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.tips.2023.09.006","article-title":"Celiac disease: mechanisms and emerging therapeutics","volume":"44","author":"Besser","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2024.104113_b0150","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3390\/ijms24020945","article-title":"New developments in celiac disease treatment","volume":"24","author":"Machado","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104113_b0155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/ph17010004","article-title":"Emerging pharmaceutical therapies to address the inadequacy of a gluten-free diet for celiac disease","volume":"17","author":"Crepaldi","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2024.104113_b0160","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.gastro.2024.02.050","article-title":"How future pharmacologic therapies for celiac disease will complement the gluten-free diet","volume":"167","author":"Discepolo","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0165","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3748\/wjg.v30.i11.1545","article-title":"Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet","volume":"30","author":"Stefanolo","year":"2024","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2024.104113_b0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","article-title":"A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease","volume":"85","author":"Catassi","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.drudis.2024.104113_b0175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.gastro.2016.11.004","article-title":"No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease","volume":"152","author":"Murray","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0180","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","article-title":"Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease","volume":"146","author":"L\u00e4hdeaho","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0185","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1053\/j.gastro.2022.07.071","article-title":"Latiglutenase protects the mucosa and attenuates symptom severity in patients with celiac disease exposed to a gluten challenge","volume":"163","author":"Murray","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0190","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1007\/s10620-017-4687-7","article-title":"Latiglutenase improves symptoms in seropositive celiac disease patients while on a gluten-free diet","volume":"62","author":"Syage","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.drudis.2024.104113_b0195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2021.03.019","article-title":"Gluten degradation, pharmacokinetics, safety, and tolerability of TAK-062, an engineered enzyme to treat celiac disease","volume":"161","author":"Pultz","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0200","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10620-016-4426-5","article-title":"AGY, a novel egg yolk-derived anti-gliadin antibody, is safe for patients with celiac disease","volume":"62","author":"Sample","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.drudis.2024.104113_b0205","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.3390\/ijms23147513","article-title":"Type 2 transglutaminase in coeliac disease: a key player in pathogenesis, diagnosis and therapy","volume":"23","author":"Paolella","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104113_b0210","doi-asserted-by":"crossref","first-page":"10815","DOI":"10.3390\/ijms241310815","article-title":"The oral transglutaminase 2 inhibitor ZED1227 accumulates in the villous enterocytes in celiac disease patients during gluten challenge and drug treatment","volume":"24","author":"Isola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104113_b0215","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/cells11101667","article-title":"Features of ZED1227: the first-in-class tissue transglutaminase inhibitor undergoing clinical evaluation for the treatment of celiac disease","volume":"11","author":"B\u00fcchold","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2024.104113_b0220","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"L\u00e4hdeaho","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.104113_b0225","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41590-024-01867-0","article-title":"Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease","volume":"25","author":"Dotsenko","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2024.104113_b0230","unstructured":"GSK drops celiac program acquired in Sitari buyout\u2014and delivers blow to bid to avert antibiotic apocalypse. (Press release February 01, 2023, Fierce Biotech). Accessed 19 January 2024. https:\/\/www.fiercebiotech.com\/biotech\/gsk-drops-celiac-disease-program-acquired-sitari-buyout-and-delivers-blow-bid-avert."},{"key":"10.1016\/j.drudis.2024.104113_b0235","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0240","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0245","unstructured":"Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer. (Press release May 25, 2023). Accessed 19 January 2024. https:\/\/topas-therapeutics.com\/topas-therapeutics-initiates-phase-2a-clinical-trial-for-tpm502-in-celiac-disease-appoints-chief-business-officer-and-chief-operating-officer\/."},{"key":"10.1016\/j.drudis.2024.104113_b0250","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S2468-1253(23)00107-3","article-title":"Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial","volume":"8","author":"Murray","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.104113_b0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/imr.12191","article-title":"IL-15: a central regulator of celiac disease immunopathology","volume":"260","author":"Abadie","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2024.104113_b0260","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.104113_b0265","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/19420862.2017.1332553","article-title":"Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis","volume":"9","author":"Vicari","year":"2017","journal-title":"Mabs"},{"key":"10.1016\/j.drudis.2024.104113_b0270","doi-asserted-by":"crossref","first-page":"S-789","DOI":"10.1016\/S0016-5085(24)00940-5","article-title":"CALY-002, an anti-IL-15 antibody, prevents gluten challengeinduced mucosal damage and inflammation: results from a phase 1A\/B study","volume":"166","author":"Schumann","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0275","unstructured":"TEV-CeD study. Accessed 19 January 2024. https:\/\/tevstudy.celiac.org\/."},{"key":"10.1016\/j.drudis.2024.104113_b0280","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/j.gastro.2019.10.006","article-title":"Identification of a \u03b3c receptor antagonist that prevents reprogramming of human tissue-resident cytotoxic T cells by IL15 and IL21","volume":"158","author":"Ciszewski","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0285","unstructured":"Equillium announces update on multi-cytokine inhibitors EQ101 & EQ102 in development for alopecia areata and celiac disease. (Press release December 21, 2023). Accessed 19 January 2024. https:\/\/www.equilliumbio.com\/investors\/press-releases\/news-details\/2023\/Equillium-Announces-Update-on-Multi-Cytokine-Inhibitors-EQ101--EQ102-in-Development-for-Alopecia-Areata-and-Celiac-Disease\/default.aspx."},{"key":"10.1016\/j.drudis.2024.104113_b0290","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1038\/s41467-023-44083-4","article-title":"Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease","volume":"14","author":"Okura","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2024.104113_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110259","article-title":"A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease","volume":"264","author":"Hardy","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.drudis.2024.104113_b0300","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.drudis.2024.104113_b0305","unstructured":"Ritlecitinib. Accessed 19 January 2024. https:\/\/go.drugbank.com\/drugs\/DB14924."},{"key":"10.1016\/j.drudis.2024.104113_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.05.022","article-title":"Enduring clinical remission in refractory celiac disease type II with tofacitinib: an open-label clinical study","author":"Dieckman","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.104113_b0315","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jcmgh.2016.12.006","article-title":"Celiac disease: role of the epithelial barrier","volume":"3","author":"Schumann","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2024.104113_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.717925","article-title":"The role of intestinal permeability in gastrointestinal disorders and current methods of evaluation","volume":"8","author":"Vanuytsel","year":"2021","journal-title":"Front Nutr"},{"key":"10.1016\/j.drudis.2024.104113_b0325","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/med.21753","article-title":"Emerging roles of SIRT6 in human diseases and its modulators","volume":"41","author":"Liu","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2024.104113_b0330","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.tcb.2021.06.009","article-title":"Sirtuin 6: linking longevity with genome and epigenome stability","volume":"31","author":"Korotkov","year":"2021","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.drudis.2024.104113_b0335","unstructured":"Immunic reports positive results from Phase 1b clinical trial of IMU-856 in celiac disease, providing clinical proof-of-concept for new therapeutic approach to gastrointestinal disorders (Press release May 4, 2023). Accessed 19 January 2024. https:\/\/imux.com\/immunic-reports-positive-results-from-phase-1b-clinical-trial-of-imu-856-in-celiac-disease-providing-clinical-proof-of-concept-for-new-therapeutic-approach-to-gastrointestinal-disorders\/."},{"key":"10.1016\/j.drudis.2024.104113_b0340","unstructured":"9 Meters Biopharma announces interim analysis of Phase 3 study of larazotide for celiac disease does not support trial continuation. (Press release June 21, 2022). Accessed 19 January 2024. https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=4598003219390084."},{"key":"10.1016\/j.drudis.2024.104113_b0345","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1007\/s00394-020-02324-y","article-title":"Role of the gut microbiota in the pathogenesis of coeliac disease and potential therapeutic implications","volume":"59","author":"Akobeng","year":"2020","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.drudis.2024.104113_b0350","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41385-021-00479-3","article-title":"The double-edged sword of gut bacteria in celiac disease and implications for therapeutic potential","volume":"15","author":"Galipeau","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.drudis.2024.104113_b0355","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1053\/j.gastro.2021.08.016","article-title":"Co-factors, microbes, and immunogenetics in celiac disease to guide novel approaches for diagnosis and treatment","volume":"161","author":"Verdu","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104113_b0360","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4161\/gmic.1.3.11868","article-title":"Effects of a gluten-free diet on gut microbiota and immune function in healthy adult humans","volume":"1","author":"Sanz","year":"2010","journal-title":"Gut Microbes"},{"key":"10.1016\/j.drudis.2024.104113_b0365","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3390\/biomedicines11102638","article-title":"Gut microbiota alteration and its modulation with probiotics in celiac disease","volume":"11","author":"Saviano","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2024.104113_b0370","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4291\/wjgp.v11.i6.114","article-title":"Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases","volume":"11","author":"Muehler","year":"2020","journal-title":"World J Gastrointest Pathophysiol"},{"key":"10.1016\/j.drudis.2024.104113_b0375","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.14309\/ajg.0000000000000759","article-title":"Healthcare resource utilization and costs in celiac disease: a US claims analysis","volume":"115","author":"Cappell","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.drudis.2024.104113_b0380","first-page":"172","article-title":"The economic iceberg of celiac disease: more than the cost of gluten-free food","volume":"167","author":"Bozorg","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T21:31:52Z","timestamp":1725053512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624002381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1359644624002381"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104113","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New developments in celiac disease treatments","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104113"}}